ETF Holdings Breakdown of AMLX

AMLX institutional holdings

The adjusted close for AMLX on 2025-11-11 was 12.68

The following institutional investment holdings of AMLX have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	90,761	USD 1,150,849 3.9%	12.68
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	57,263	USD 726,095 3.9%	12.68
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	57,263	USD 726,095 3.9%	12.68
Total =		205,287	USD 2,603,039

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with AMLX

Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 1-Year High on Analyst Upgrade

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday after The Goldman Sachs Group raised their price target on the stock from $10.00 to $20.00. The Goldman Sachs Group currently has a buy rating on the stock. Amylyx Pharmaceuticals traded as high as $12.40 and last […] - 2025-09-19 02:18:53

Guggenheim Raises Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $25.00

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) had its price objective hoisted by equities researchers at Guggenheim from $17.00 to $25.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target suggests a potential upside of 109.03% from the company’s […] - 2025-09-17 02:46:45

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $11.75 Average Target Price from Analysts

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) has been assigned an average rating of “Buy” from the thirteen research firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to […] - 2025-08-06 02:31:00

Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday. Several other research analysts also recently weighed in on AMLX. Leerink Partners upgraded shares of Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating […] - 2025-07-21 02:16:48

Alps Advisors Inc. Grows Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Alps Advisors Inc. lifted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 22.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 67,597 shares of the company’s stock after buying an additional 12,167 shares during the quarter. Alps Advisors […] - 2025-07-18 04:58:53

Guggenheim Initiates Coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX)

Guggenheim began coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) in a report issued on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $17.00 price target on the stock. Guggenheim’s price target indicates a potential upside of 171.57% from the stock’s previous close. AMLX has been the topic […] - 2025-06-26 02:48:52

209,708 Shares in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Acquired by Wellington Management Group LLP

Wellington Management Group LLP acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 209,708 shares of the company’s stock, valued at approximately $793,000. Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. […] - 2025-06-08 05:50:58

Mackenzie Financial Corp Has $421,000 Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Mackenzie Financial Corp increased its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 234.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 111,310 shares of the company’s stock after purchasing an additional 78,070 shares during the period. Mackenzie Financial Corp’s holdings in Amylyx Pharmaceuticals were worth $421,000 as […] - 2025-06-04 05:57:00

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP lowered its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 22.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 241,400 shares of the company’s stock after selling 68,100 shares during the quarter. Two Sigma Advisers LP owned […] - 2025-06-02 05:53:04

State of Wyoming Decreases Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

State of Wyoming decreased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 37.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 16,077 shares of the company’s stock after selling 9,700 shares during the period. State of Wyoming’s holdings in Amylyx Pharmaceuticals were worth $61,000 as of its most recent filing with […] - 2025-05-29 04:50:51

Jane Street Group LLC Raises Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Jane Street Group LLC lifted its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 122.4% in the fourth quarter, HoldingsChannel reports. The firm owned 765,475 shares of the company’s stock after purchasing an additional 421,302 shares during the quarter. Jane Street Group LLC’s holdings in Amylyx Pharmaceuticals were worth $2,893,000 at the end […] - 2025-05-14 05:30:54

Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $16.00

Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its price objective raised by HC Wainwright from $12.00 to $16.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock. AMLX has been the subject of several other reports. Mizuho upgraded Amylyx Pharmaceuticals from a “neutral” rating to […] - 2025-05-12 05:12:49

Marshall Wace LLP Decreases Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Marshall Wace LLP decreased its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 35.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 184,678 shares of the company’s stock after selling 99,308 shares during the quarter. Marshall Wace LLP’s holdings in Amylyx […] - 2025-05-02 05:30:59

XTX Topco Ltd Purchases 5,704 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

XTX Topco Ltd increased its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 12.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,376 shares of the company’s stock after acquiring an additional 5,704 shares during the period. XTX […] - 2025-04-28 05:48:57

Renaissance Technologies LLC Has $1.76 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Renaissance Technologies LLC raised its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 70.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 464,400 shares of the company’s stock after buying an additional 192,600 shares during […] - 2025-04-28 04:44:59

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong […] - 2025-04-25 03:12:51

Federated Hermes Inc. Has $765,000 Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Federated Hermes Inc. raised its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 8.6% during the 4th quarter, HoldingsChannel reports. The firm owned 202,316 shares of the company’s stock after purchasing an additional 16,030 shares during the quarter. Federated Hermes Inc.’s holdings in Amylyx Pharmaceuticals were worth $765,000 as of its […] - 2025-04-16 05:15:06

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $7.33 Average Price Target from Brokerages

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued […] - 2025-04-03 02:36:46

13,909 Shares in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Bought by EntryPoint Capital LLC

EntryPoint Capital LLC purchased a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 13,909 shares of the company’s stock, valued at approximately $53,000. Several other hedge funds have […] - 2025-03-31 05:32:51

Fox Run Management L.L.C. Acquires Shares of 11,788 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Fox Run Management L.L.C. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 11,788 shares of the company’s stock, valued at approximately $45,000. Several other hedge funds have also modified their […] - 2025-03-30 05:50:47

Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating […] - 2025-02-12 05:00:52

Back to Listing

Disclaimer